Latest filings (excl ownership)
6-K
Report on Voting Results
10 May 24
6-K
Theratechnologies Reports on its Annual Meeting of Shareholders
9 May 24
6-K
Notice of Annual Meeting of Shareholders
15 Apr 24
6-K
Interim Consolidated Financial Statements
10 Apr 24
6-K
Theratechnologies Reports Financial Results
10 Apr 24
6-K
Theratechnologies Appoints Elina Tea to its Board of Directors
5 Apr 24
6-K
Theratechnologies Announces Update on its Preclinical Oncology Research Program
22 Mar 24
6-K
Theratechnologies Appoints Jordan Zwick to its Board of Directors
22 Mar 24
6-K
Current report (foreign)
21 Mar 24
6-K
Theratechnologies Announces the Resignation of One of Its
29 Feb 24
6-K
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular
27 Feb 24
20-F
2023 FY
Annual report (foreign)
21 Feb 24
6-K
Theratechnologies Reports Financial Results
21 Feb 24
6-K
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
15 Feb 24
6-K
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial
6 Feb 24
6-K
Material Change Report
1 Feb 24
6-K
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
24 Jan 24
6-K
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental
23 Jan 24
EFFECT
Notice of effectiveness
4 Jan 24
F-3/A
Shelf registration (foreign) (amended)
2 Jan 24
CORRESP
Correspondence with SEC
2 Jan 24
UPLOAD
Letter from SEC
27 Dec 23
6-K
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
21 Dec 23
F-3
Shelf registration (foreign)
21 Dec 23
6-K
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
13 Dec 23
6-K
Material Change Report
6 Nov 23
6-K
Investor Rights Agreement
6 Nov 23
6-K
First Amendment to Credit Agreement
3 Nov 23
6-K
Theratechnologies Announces Closing of US$25 Million Public Offering of
31 Oct 23
6-K
Current report (foreign)
26 Oct 23
SUPPL
Supplemental materials (foreign)
26 Oct 23
6-K
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
26 Oct 23
SUPPL
Supplemental materials (foreign)
25 Oct 23
F-X
Appointment of agent for service of process by issuers registering securities
25 Oct 23
6-K
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
25 Oct 23
6-K
Material Change Report
24 Oct 23
6-K
Theratechnologies Announces Operational Update
24 Oct 23
6-K
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
16 Oct 23
6-K
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
26 Sep 23
6-K
Interim Consolidated Financial Statements
26 Sep 23
Latest ownership filings
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
HIRSCHMAN ORIN
29 Nov 23
SC 13D
Soleus Capital Master Fund, L.P.
28 Nov 23
SC 13D
Investissement Quebec
13 Nov 23
SC 13G/A
Soleus Capital Master Fund, L.P.
14 Feb 23
SC 13G/A
MORGAN STANLEY
10 Feb 23
SC 13G/A
Soleus Capital Master Fund, L.P.
14 Nov 22
SC 13G
MORGAN STANLEY
11 Feb 22
SC 13G/A
Soleus Capital Master Fund, L.P.
10 Feb 22
SC 13G/A
STEWARDSHIP PARTNERS INVESTMENT COUNSEL, INC.
10 Feb 22
SC 13G
Soleus Capital Master Fund, L.P.
23 Feb 21
SC 13G/A
STEWARDSHIP PARTNERS INVESTMENT COUNSEL, INC.
11 Feb 21
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G/A
Theratechnologies Inc.
8 Feb 19
SC 13G/A
Theratechnologies Inc.
13 Feb 18
SC 13G/A
Theratechnologies Inc.
7 Feb 17
SC 13G/A
Theratechnologies Inc.
11 Feb 16
SC 13G
Theratechnologies Inc.
11 Feb 15
SC 13G/A
Theratechnologies Inc.
6 Feb 15
SC 13G/A
Theratechnologies Inc.
7 Feb 14